efficaci kra nsclc reiter buy
springwork went public septemb prior quarterli
financi data limit
unsurprisingli keytruda seem effect kra nsclc
yesterday merck rate present result
trial keytruda monotherapi
keytruda chemo respect front-lin kra non-
squamou non-smal cell lung cancer nsclc european
societi medic oncolog esmo immuno-oncolog confer
geneva switzerland keytruda monotherapi
exhibit median progression-fre surviv mpf month
month nsclc patient kra mutat
kra mutat respect compar six-month
mpf nsclc chemo-tr patient kra mutat
kra mutat yield
hr hr respect keytruda
monotherapi also demonstr median overal surviv mo
month mo reach nsclc patient
kra mutat kra mutat respect
compar favor mo nsclc
chemo-tr patient either kra mutat kra
mutationthi yield os hr os hr
respect respons rate keytruda monotherapi
kra nsclc rang keytruda chemo vs
chemo also appear efficaci benefit least regard
hr os
hr hr os hr
patient kra mutat kra mutat
respect per abstract sampl size rel
small find find surpris sinc previou data
allud efficaci benefit i/o agent kra nsclc
highlight recent initi report spring bloom cancer
patient initi buy price
find efficaci benchmark insurmount
respons rate keytruda monotherapi kra nsclc
appear similar seen
feel target ra pathway and/or mutant-select kra
agent could still deliv superior mpf and/or mo although
apples-to-appl comparison point efficaci data
mutation-select agents/regimen novarti nv rate
tafinlar mekinist demonstr mpf
mo braf nsclc astrazeneca azn rate
tagrisso mpf mo egfr
nsclc phase flaura trial roch rog sw rate
alectinib demonstr mpf previous untreat
nsclc phase trial rate
xalkori crizotinib demonstr mpf
mo target agent naiv nsclc phase
trial moreov could potenti combin
target ra pathway mutant-select kra agent anti-
find prematur alter mirdametinib kra
nsclc forecast see data reiter buy rate
definit distribut analyst rate analyst certif disclosur pleas refer page report
valuat risk valu springwork use discount cash flow dcf -base valuat assess
employ probabl launch nirogacestat desmoid tumor mirdametinib associ pn along
probabl launch nirogacestat multipl myeloma probabl launch mirdametinib
kra mutat tumor util discount rate termin growth rate along effect tax rate
paramet collect yield project market valu firm roughli translat price
object assum share outstand risk includ limit clinic setback
nirogacestat and/or mirdametinib inabl submit regulatori file approv time manner failur
obtain market author nirogacestat and/or mirdametinib inabl success commerci nirogacestat and/
mirdametinib setback clinic program possibl long-term dilut risk
thousand except per share data
compani report wainwright co estim
sales- royalti fee revenues- total revenue- expensescost sales- research gener sell marketing- total gain loss income/expenseinterest incom total invest incom equiti invest loss- loss benefit provis incom benefit provis incom taxes- net incom net gain attribut extinguish convert prefer shares- net incom loss attribut common net loss per share net loss per share weight averag number share outstand weight averag number share outstand springwork therapeut inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc swtx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
raghuram selvaraju ph robert burn certifi view express report accur reflect
person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur springwork
therapeut inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic
within twelv month seek compens compani mention report invest bank
servic within three month follow public research report
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
